- Home
- GCMGW vs MRK Comparison
GCMGW vs MRK Comparison
Compare GCMGW & MRK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GCMGW
- MRK
- Stock Information
- Founded
- GCMGW 1971
- MRK 2000
- Country
- GCMGW United States
- MRK United States
- Employees
- GCMGW 549
- MRK N/A
- Industry
- GCMGW Finance/Investors Services
- MRK Biotechnology: Pharmaceutical Preparations
- Sector
- GCMGW Finance
- MRK Health Care
- Exchange
- GCMGW Nasdaq
- MRK Nasdaq
- Market Cap
- GCMGW N/A
- MRK 218.8B
- IPO Year
- GCMGW N/A
- MRK N/A
- Fundamental
- Price
- GCMGW N/A
- MRK $84.81
- Analyst Decision
- GCMGW
- MRK Buy
- Analyst Count
- GCMGW 0
- MRK 15
- Target Price
- GCMGW N/A
- MRK $105.14
- AVG Volume (30 Days)
- GCMGW 62.4K
- MRK 13.7M
- Earning Date
- GCMGW 02-13-2025
- MRK 10-30-2025
- Dividend Yield
- GCMGW N/A
- MRK 3.83%
- EPS Growth
- GCMGW N/A
- MRK 20.41
- EPS
- GCMGW 0.03
- MRK 6.49
- Revenue
- GCMGW $514,011,999.00
- MRK $63,616,000,000.00
- Revenue This Year
- GCMGW N/A
- MRK $1.84
- Revenue Next Year
- GCMGW N/A
- MRK $5.24
- P/E Ratio
- GCMGW $33.02
- MRK $13.06
- Revenue Growth
- GCMGW 15.79
- MRK 1.82
- 52 Week Low
- GCMGW $2.28
- MRK $73.31
- 52 Week High
- GCMGW $2.50
- MRK $111.58
- Technical
- Relative Strength Index (RSI)
- GCMGW 27.85
- MRK 50.79
- Support Level
- GCMGW $0.12
- MRK $86.20
- Resistance Level
- GCMGW $0.63
- MRK $88.24
- Average True Range (ATR)
- GCMGW 0.08
- MRK 2.31
- MACD
- GCMGW -0.09
- MRK 0.08
- Stochastic Oscillator
- GCMGW 4.55
- MRK 53.84
About GCMGW GCM Grosvenor Inc.
GCM Grosvenor Inc is a world-wide alternative asset management firm. It invests on behalf of clients who seek allocations to alternative investments, such as private equity, infrastructure, real estate, credit, ESG and absolute return strategies. Company invest maximum in Private Equity. The company's offerings include multi-manager portfolios as well as portfolios of direct investments and co-investments.
About MRK Merck & Company Inc. (new)
Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform, led by Keytruda, is a major contributor to overall sales. The company also has a substantial vaccine business aimed at preventing pediatric diseases, as well as Gardasil for human papillomavirus. Additionally, Merck sells animal health-related drugs. From a geographical perspective, 47% of the company's sales are generated from US human health (pharmaceuticals and vaccines).